Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:CMPS NASDAQ:IMVT NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$133.30+38.6%$111.04$7.41▼$148.83$7.67B0.693.11 million shs8.91 million shsCMPSCompass Pathways$14.15-6.1%$11.29$2.82▼$15.40$2.03B2.53.16 million shs3.46 million shsIMVTImmunovant$38.55+0.1%$31.88$14.32▼$39.28$7.91B0.761.68 million shs1.41 million shsPTGXProtagonist Therapeutics$122.58+0.8%$105.08$49.38▼$126.59$7.82B1.85840,294 shs560,872 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+38.64%+35.42%+0.50%+15.94%+1,642.46%CMPSCompass Pathways-6.10%+11.86%+8.35%+151.78%+405.36%IMVTImmunovant+0.11%+2.48%+15.77%+53.59%+140.95%PTGXProtagonist Therapeutics+0.78%+3.04%+23.12%+18.24%+121.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$133.30+38.6%$111.04$7.41▼$148.83$7.67B0.693.11 million shs8.91 million shsCMPSCompass Pathways$14.15-6.1%$11.29$2.82▼$15.40$2.03B2.53.16 million shs3.46 million shsIMVTImmunovant$38.55+0.1%$31.88$14.32▼$39.28$7.91B0.761.68 million shs1.41 million shsPTGXProtagonist Therapeutics$122.58+0.8%$105.08$49.38▼$126.59$7.82B1.85840,294 shs560,872 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+38.64%+35.42%+0.50%+15.94%+1,642.46%CMPSCompass Pathways-6.10%+11.86%+8.35%+151.78%+405.36%IMVTImmunovant+0.11%+2.48%+15.77%+53.59%+140.95%PTGXProtagonist Therapeutics+0.78%+3.04%+23.12%+18.24%+121.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.81Moderate Buy$144.468.37% UpsideCMPSCompass Pathways 3.00Buy$23.1063.25% UpsideIMVTImmunovant 2.45Hold$39.702.98% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$115.21-6.01% DownsideCurrent Analyst Ratings BreakdownLatest CMPS, IMVT, PTGX, and ABVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026ABVXAbivax HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026ABVXAbivax GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$57.00 ➝ $61.006/30/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$150.00 ➝ $175.006/30/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$108.00 ➝ $158.006/30/2026ABVXAbivax Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$140.00 ➝ $148.006/30/2026ABVXAbivax WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$90.00 ➝ $110.006/26/2026CMPSCompass Pathways Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.006/16/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/ACMPSCompass PathwaysN/AN/AN/AN/A($0.55) per shareN/AIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/APTGXProtagonist Therapeutics$46.02M171.30N/AN/A$9.83 per share12.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/14/2026 (Estimated)CMPSCompass Pathways-$287.86M-$3.15N/AN/AN/AN/A-31.07%-11.40%7/30/2026 (Estimated)IMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)Latest CMPS, IMVT, PTGX, and ABVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/13/2026Q1 2026CMPSCompass Pathways-$0.45-$0.30+$0.15-$0.30N/AN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ACMPSCompass PathwaysN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25CMPSCompass Pathways0.153.323.32IMVTImmunovantN/A9.099.09PTGXProtagonist TherapeuticsN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%CMPSCompass Pathways46.19%IMVTImmunovant47.08%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/ACMPSCompass Pathways2.82%IMVTImmunovant1.80%PTGXProtagonist Therapeutics5.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.77 millionN/ANot OptionableCMPSCompass Pathways120134.95 million131.14 millionOptionableIMVTImmunovant120205.31 million201.61 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableCMPS, IMVT, PTGX, and ABVX HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Boosts Stock Position in Protagonist Therapeutics, Inc. $PTGXJune 30 at 4:55 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High - Should You Buy?June 29 at 10:59 AM | marketbeat.comLouisiana State Employees Retirement System Makes New $2.75 Million Investment in Protagonist Therapeutics, Inc. $PTGXJune 29 at 4:48 AM | marketbeat.comWilliam Waddill Sells 9,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) StockJune 27, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Cut to "Buy" at Wall Street ZenJune 27, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Lowered to "Buy" Rating by Wall Street ZenJune 27, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 SharesJune 26, 2026 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 24, 2026 | americanbankingnews.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 24, 2026 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Purchased by Perceptive Advisors LLCJune 18, 2026 | marketbeat.comElmind Capital LP Takes $3.32 Million Position in Protagonist Therapeutics, Inc. $PTGXJune 18, 2026 | marketbeat.comEversept Partners LP Takes Position in Protagonist Therapeutics, Inc. $PTGXJune 18, 2026 | marketbeat.comCommodore Capital LP Has $39.30 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGXJune 18, 2026 | marketbeat.comProtagonist Therapeutics Reports Granting of Inducement AwardsJune 16, 2026 | accessnewswire.comAProtagonist Therapeutics (NASDAQ:PTGX) Hits New 52-Week High - Time to Buy?June 16, 2026 | marketbeat.comNEXTBio Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGXJune 14, 2026 | marketbeat.comKennedy Capital Management LLC Buys 13,007 Shares of Protagonist Therapeutics, Inc. $PTGXJune 14, 2026 | marketbeat.com10,000 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Dymon Asia Capital Singapore PTE. LTD.June 14, 2026 | marketbeat.comProtagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On GoalJune 13, 2026 | seekingalpha.comKeystone Investors PTE Ltd. Buys Shares of 26,390 Protagonist Therapeutics, Inc. $PTGXJune 13, 2026 | marketbeat.comGoldman Sachs Remains a Hold on Protagonist Therapeutics (PTGX)June 13, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPS, IMVT, PTGX, and ABVX Company DescriptionsAbivax NASDAQ:ABVX$133.30 +37.15 (+38.64%) Closing price 06/30/2026 03:59 PM EasternExtended Trading$135.91 +2.61 (+1.96%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Compass Pathways NASDAQ:CMPS$14.15 -0.92 (-6.10%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$14.32 +0.17 (+1.24%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Immunovant NASDAQ:IMVT$38.55 +0.04 (+0.11%) Closing price 06/30/2026 03:59 PM EasternExtended Trading$39.20 +0.65 (+1.68%) As of 05:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Protagonist Therapeutics NASDAQ:PTGX$122.58 +0.95 (+0.78%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$122.32 -0.26 (-0.21%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
